Navigation Links
Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
Date:10/29/2007

KING OF PRUSSIA, Pa., Oct. 29 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today announced development of an orally active form of semapimod, its synthetic anti-cytokine compound. Semapimod is a potential treatment for inflammatory and autoimmune diseases including rheumatoid arthritis, Crohn's and psoriasis. The compound has previously been tested in clinical trials only as an intravenous infusion and the newly developed oral form should significantly enhance its acceptability to patients and physicians.

Semapimod is a synthetic guanylhydrazone that inhibits the activity of various kinases, including Raf kinase, a key enzyme in the MAPK/ERK signal transduction pathway. Semapimod's inhibition of Raf-kinase decreases phosphorylation of MEK, thereby also inhibiting phosphorylation of p38 MAP kinase. This halts production of several important inflammatory cytokines, including TNF-alpha, IL-1, and IL-6. Preclinical studies have repeatedly demonstrated semapimod's efficacy in animal models of inflammatory and proliferative diseases, including endotoxic shock and toxicity, pancreatitis, ischemia and stroke, necrotizing enterocolitis, and neointimal formation. Despite early signals of efficacy, the Phase II studies CPSI conducted in Crohn's disease were dose-limited by local reactions (i.e., phlebitis) to the semapimod-HCl formulation. These reactions led to the need to develop a less irritating intravenous (IV) form. In response, CPSI has developed a new salt form of semapimod with a dramatically improved solubility and tolerability profile, which ultimately resulted in the new orally available formulation.

Dr. Daan W. Hommes, (University of Leiden; formerly with the Academic Medical Center, Amsterdam, The Netherlands) tested an IV formulation of semapimod in an early Crohn's disease study. He commented: "The early work with semapimod showed the promise of this drug. Continued development would benefit from improved dosing regimens."

Dr. Marco Bruno (AMC, Amsterdam, The Netherlands) tested semapimod IV for prevention of ERCP-induced pancreatitis. He stated: "The trial showed a clear trend toward efficacy when semapimod was used prophylactically. The reductions in the pancreatitis rate and amylase levels were impressive when one considers that this was a single dose treatment where we did not know the optimal dose. Larger scale studies are clearly warranted."

The ability to dose orally is viewed as a considerable advance in the development of semapimod. Dr. Thais Sielecki, Director of Research at CPSI, commented: "As a synthetic small-molecule, semapimod holds the promise of a more cost-effective alternative to expensive and difficult-to-manufacture biologics. Oral dosing would also make treatment much easier than the IV and subcutaneous routes, which are currently the only options for many patients."

The new salts have demonstrated their ability to reduce cytokine levels when given orally in a preclinical sepsis model. CPSI has recently obtained a patent on these new salts (US 7,244,765), giving considerable patent life for the reformulated product.

The company is ready to move these new salts into clinical trials and is seeking a partner to assist with their development plan.

About Cytokine PharmaSciences, Inc.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, visit to http://www.cytokinepharmasciences.com.


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... , June 23, 2016 , ... Thursday, July 7, 2016 , , , , LOCATION: , ... , , , , EXPERT PANELISTS:  , , , Frost ... Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh ... The global pharmaceutical industry is witnessing an exceptional era. Several ...
Breaking Medicine Technology:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
Breaking Medicine News(10 mins):